Latest News
Secura Bio Acquires Rights to Farydak from Novartis
Thursday 14 March 2019

14 March 2019 - Nevada, US-based commercial stage biopharmaceutical company Secura Bio, Inc. has acquired the global rights to Farydak (panobinostat) from Novartis for treating multiple myeloma, the company said.

Terms of the transaction were not disclosed.

Farydak has received FDA accelerated approval for use in patients with multiple myeloma, and on August 28, 2015 it was approved by the European Medicines Agency for the same use. Farydak has received marketing authorisation in 53 countries to date for the treatment of patients with multiple myeloma.

Secura Bio is dedicated to working with health care professionals to ensure Farydak's benefit to patients is well understood by cancer care teams and by ensuring that the medicine is available to those who need it. Secura Bio is also investigating the opportunity to develop new potential dosages and product combinations for Farydak.

Farydak is a member of the histone deacetylase inhibitor family with a very potent and unique mode of action slowing the growth of multiple myeloma cells.

Secura Bio, Inc. is an integrated, commercial-stage biopharmaceutical company dedicated to the worldwide commercialisation of significant oncology therapies for physicians and their patients.
Date Published: 14/03/2019
Target: Global rights to Farydak (panobinostat)
Country: USA
Sector: Pharmaceuticals
Type: Corporate acquisition
Status: Closed
Vendor: Novartis
Buyer: Secura Bio, Inc
Terms of the deal were not disclosed